ACETO Corp (ACET) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
BTIG Reiterates Buy Rating on Adicet Bio Inc. (ACET)
August 14, 2024 6:11 AM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $6.00 price target on Adicet Bio Inc. (NASDAQ: ACET).
The analyst comments "Adicet reported 2Q24 earnings, with expansion of ADI-001 autoimmune clinical development beyond lupus nephritis to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil... More
